410 results about "Metabolic function" patented technology

The invention discloses an intelligent nutrition and metabolism management system for tumor patients, and particularly relates to the technical field of intelligent management. Comprising a patient treatment duration division module, a patient treatment nutrition and metabolism information acquisition module, a patient treatment nutrition intelligent management module, a patient metabolism risk intelligent evaluation module, an auxiliary decision data analysis module, a patient treatment effect intelligent early warning module and a patient treatment nutrition and metabolism intelligent optimization module. According to the invention, the nutrition and metabolism monitoring data of each sub-period of the disease treatment duration of the target patient is collected, the nutrition state evaluation index and the metabolism function risk management index are calculated, and the patient treatment effect early warning index is obtained through analysis, so that the nutrition and metabolism conditions of the patient are intervened, the treatment effect evaluation accuracy is improved, and the patient treatment efficiency is improved. Waste of medical resources is reduced, and intelligent development of treatment effect decision making is promoted.

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici ZJUIDS13 in improvement of liver diseases, including improvement of alcoholic liver diseases and improvement of fatty liver diseases related to metabolic dysfunction. The pediococcus acidilactici ZJUIDS13 has relatively strong capability of protecting liver injury induced by alcohol, and can improve the states of liver injury and lipid metabolism disorder caused by high fat diet.

The invention provides application of macrophage PHGDH in preparation of a TAK1 inhibitor, and belongs to the technical field of biological medicine. The invention finds that the PA-induced inflammation can be promoted by knocking down the PHGDH in the macrophage. In addition, the macrophage specific PHGDH is combined with TAK1, and the interaction between TAK1 and TAB1 is inhibited, so that the activation of TAK1 and downstream NF-kB and MAPK signal transduction are inhibited. Development of metabolic dysfunction related steatohepatitis MASH caused by medullary system PHGDH knockout can be slowed down by inhibiting TAK1 activation. What's more important is that the MAFLD is reduced by the overexpression of the PHGDH in the adeno-associated virus mediated liver macrophages. The invention discovers that the macrophage PHGDH is a promising medicine for treating MAFLD (MAFF-induced leukemia disease).

The invention discloses application of a bifidobacterium animalis subspecies F1-7 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-7 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of drugs for improving bile acid metabolic function decline caused by sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of a medicine for improving intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-7 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, regulate intestinal flora, promote bile acid metabolism and further relieve muscular atrophy, and enriches a probiotic library for improving sarcopenia.

The utility model provides a thermal steaming type belly health care waistband which comprises a waistband body tied to the waist and belly of a human body, a breathable storage bag used for containing a traditional Chinese medicine bag is arranged on the inner side wall, right facing the belly of the human body, of the waistband body, and a water vapor generating device is arranged on the outer side wall, right facing the belly of the human body, of the waistband body. The water vapor generating device is right opposite to the storage bag, air holes communicated with the storage bag are formed in the outer side wall, right opposite to the abdomen of the human body, of the waistband body, and hot steam generated by the water vapor generating device enters the storage bag through the air holes to conduct hot steaming on a traditional Chinese medicine bag placed in the storage bag. The medicinal materials in the traditional Chinese medicine bag are promoted to release medicinal gas by utilizing a hot steaming principle, so that the medicinal gas is fully released and acts on the abdomen of a human body, and the effects of the traditional Chinese medicines are improved, thereby improving the hormone level in the body and regulating the metabolic function and endocrine function.

Provided herein is a method for the screening of patients with at-risk MASH (metabolic dysfunction-associated steatohepatitis, formerly named nonalcoholic steatohepatitis or NASH). The combination of levels of five circulating markers, i.e. alanine aminotransferase (ALAT), aspartate transaminase (ASAT), platelets, hsa-miR-34a and YKL-40 in a subject, and eventually the age and gender of said subject, allows to accurately identify non-cirrhotic at-risk MASH. The information obtained from the levels of these markers also allows to screen a subject as being eligible to liver biopsy and / or to classify a subject as a receiver or non-receiver of a treatment of MASH and / or to classify a subject as a responder or non-responder of a treatment of MASH.

The method of treating obesity and targeting adipose tissue in a patient may use injection of a polycationic polymer, such as polyamidoamine (PAMAM) generation 3 (P-G3) or a PCL-g-PAMAM Denpol, that when delivered intraperitoneally, selectively targets visceral adiposity due to its high charge density. P-G3 treatment of obese mice inhibits visceral adiposity, increases energy expenditure, prevents obesity, and alleviates associated metabolic dysfunctions. The extracellular matrix of adipose tissue is enriched with glycosaminoglycans, the known biomacromolecules with the strongest negative charge. P-G3 uncouples adipocyte lipid synthesis and storage from adipocyte development, creating adipocytes with normal functions but that are deficient in hypertrophic growth. The visceral fat distribution of P-G3 is further enhanced by modifying P-G3 with cholesterol to form lipophilic nanoparticles, effective in treating obesity. This strategy provides a method to target visceral adiposity, and cationic nanomaterials useful for treating metabolic diseases or for delivery of additional treating agents.

The present invention relates to methods of treating metabolic dysfunction-associated steatohepatitis (MASH) in a human subject, comprising administering to the subject a therapeutically effective amount of indeglitazar or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to application of beta-hydroxybutyrate in preparation of a medicine for preventing or treating hepatocellular carcinoma. The invention provides an application of beta-hydroxybutyrate in preparation of a medicine for preventing and / or treating hepatocellular carcinoma. The beta-hydroxybutyrate comprises a beta-hydroxybutyrate or a combination of a plurality of beta-hydroxybutyrates. A series of experimental data show that beta-hydroxybutyrate not only can effectively improve fatty degeneration and inflammatory response of hepatocytes, but also can remarkably reduce the risk of occurrence of metabolic dysfunction related hepatocellular carcinoma (HCC), and can inhibit malignant biological characteristics of HCC. The invention provides a powerful scientific basis for the development of novel HCC prevention and treatment medicines, and has a wide clinical application prospect.

The present disclosure provides GLP-1 / GIP and GLP-1 / GCG dual receptor agonists comprising incretin analog polypeptides and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia / dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction- associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and / or obesity.

The disclosure provides methods and compositions for treating metabolic disorders, including Type 2 Diabetes, obesity, Metabolic Dysfunction-associated Steatotic Liver Disease, and other obesity-related metabolic disorders by combining localized delivery of a gene therapy to pancreatic tissue.

The invention provides a novel compound feed for leuciscus waleckii, which comprises the following components: 10 to 30 percent of fish meal, 8 to 12 percent of soybean protein concentrate, 15 to 20 percent of flour, 3 to 6 percent of casein, 0.5 to 2 percent of gelatin, 4 to 6 percent of corn protein powder, 2 to 3 percent of soybean oil, 2 to 3 percent of fish oil, 18 to 24 percent of dextrin, 0.3 to 0.6 percent of mineral substance and vitamin premix, 0.2 to 0.6 percent of choline chloride, 1.5 to 2.5 percent of monocalcium phosphate, 0.05 to 0.12 percent of vitamin C ester, 2.5 to 3.5 percent of microcrystalline cellulose and the balance of water. The non-grain novel protein source defatted tenebrio molitor powder is used for partially replacing the fish meal, and the replacement proportion is 0-60%. The invention further provides a preparation method of the novel compound feed for the leuciscus waleckii, and the obtained feed is used for the leuciscus waleckii and can promote the growth performance, the digestive function, the protein metabolism function, the lipid metabolism function, the immune function and the oxidation resistance of the leuciscus waleckii. The invention provides a theoretical reference for developing a novel non-grain protein source, saving fish meal protein, reducing the feed cost and optimizing the artificial compound feed for the leuciscus waleckii.

17-Beta-hydroxysteroid dehydrogenase type 13 (17β-HSD13) plays an important role in the pathogenesis and progression of Non-alcoholic fatty liver disease (NAFLD), also known as Metabolic dysfunction-associated steatotic liver disease (MASLD), and Alcohol-related liver disease (ARLD). Loss-of-function variant of 17β-HSD13 has been associated with a significantly reduced risk of NAFLD (MASLD), cirrhosis associated with nonalcoholic steatohepatitis (NASH (MASH)), alcoholic-related liver disease, alcoholic cirrhosis, hepatocellular carcinoma (HCC), hepatitis C chronic liver disease, pediatric liver disease, NASH (MASH) disease severity, ballooning degeneration, lobular inflammation, and fibrosis. The present invention relates to hydantoin compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use for treatment and prevention of above mentioned liver diseases.

The invention discloses a construction method of a metabolism-related fatty liver cancer (MAFLD liver cancer) mouse model, and relates to the technical field of biology. The specific construction method comprises the following steps: feeding a 7-9-week-old mouse with a high-fat and high-sugar diet for 24 weeks, inducing the mouse to form fatty liver, and causing metabolic dysfunction; injecting carbon tetrachloride into the abdominal cavity of the mouse once a week while feeding the mouse with the high-fat and high-sugar diet, and inducing the liver of the mouse to form liver cancer continuously for 24 weeks, so as to construct the MAFLD liver cancer mouse. The mouse liver constructed by the method has metabolic dysfunction, fatty liver and liver cancer lesions, and has extremely high application value in research and development of drugs for researching MAFLD liver cancer pathogenesis and fatty liver related liver cancer in the future.

The invention discloses a preparation method and application of a bovine tongue mucous membrane organoid, and relates to the technical field of organoid separation and culture. The preparation method of the ox tongue mucosa organoid comprises the following steps: treating fetal ox tongue tip tissues with digestive enzymes Dispase I, Collagenase II and Collagenase IV, separating ox tongue mucosa, cutting into pieces, treating again with pancreatin, and sieving to remove tissues and impurities; and continuously culturing by adopting a three-dimensional culture technology-matrigel embedding method and an organoid culture medium to obtain the final ox tongue mucous membrane organoid. The ox tongue mucous membrane organoid prepared by the preparation method disclosed by the invention has normal cell proliferation, differentiation and metabolism functions, and can be stably passaged under an in-vitro culture condition; the method can be widely applied to various related scientific researches such as FMDV infection mechanism research, drug screening and vaccine evaluation.

The invention discloses a traditional Chinese medicine composition for treating fatty liver diseases related to metabolic dysfunction. The traditional Chinese medicine composition is prepared from the following raw material medicines: Qu fructus aurantii, lotus leaves, semen cassiae, gynostemma pentaphylla, rhizoma alismatis, rhodiola rosea, radix salviae miltiorrhizae, pseudo-ginseng and rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition and the traditional Chinese medicine compound preparation disclosed by the invention can improve the blood sugar and blood fat levels of fatty liver diseases related to metabolic dysfunction and improve the metabolic level, are remarkable in clinical curative effect, improve the living quality of patients, have the effects of regulating qi, soothing the liver, tonifying the spleen and removing stasis, slow down liver fibrosis by improving blood sugar and blood fat metabolism, and are quick in curative effect and low in price.

The invention relates to the technical field of hyperbaric oxygen physiotherapy cabins, in particular to a terahertz wave micro hyperbaric oxygen physiotherapy cabin which comprises a cabin body, a door opening is formed in one face of the cabin body, a cabin top is installed at the top of the cabin body, and a door plate is hinged to the interior of the door opening through a hinge; the deep sea volcanic energy stone treatment device comprises a cabin, two groups of bed bodies are arranged in the cabin, the two groups of bed bodies are symmetrically mounted in the cabin, each bed body is of a hollow structure, and a plurality of terahertz wave generation modules are uniformly laid on the upper surface of each bed body through a support. The pelelith-based passive terahertz releaser formed after the pelelith-based passive terahertz releaser is combined with the ceramic matrix can continuously release terahertz waves with the frequency band of 0.1-12 THz, the vibration frequency is consistent with that of human cells, and the terahertz waves with the frequency band can repair biological enzyme and nucleic acid structure deformation caused by free radical attack and age increase through the biological resonance effect, so that the pelelith-based passive terahertz releaser can be used for repairing biological enzyme and nucleic acid structure deformation caused by free radical attack and age increase. The metabolic function is recovered from the cell molecule level, and the defect that a traditional oxygen cabin can only supply oxygen on the surface layer and cannot be deeply repaired is overcome.

The invention provides a microbial ecological interaction mechanism determination method and device, and relates to the technical field of species correlation research. The method comprises the following steps: determining N microorganisms and abundance thereof based on metagenome data of a target environment sample; determining the abundance grade and correlation based on the abundance of the ith microorganism and the jth microorganism; carrying out metabolic function annotation on the i microorganism and the j microorganism based on a reference genome, and calculating a function overlapping ratio; determining a community construction mechanism based on the abundance correlation and the function overlapping ratio; based on the function overlapping difference, determining a function overlapping grade change; and determining the ecological interaction mechanism of the i and j microorganisms according to the information. The method can be used for systematically revealing a species coexistence mechanism and a metabolic interaction relationship thereof in the microbial community.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

Method for predicting severity of COVID-19 disease resulting from infection with SARS-COV-2 (severe acute respiratory syndrome coronavirus 2). The method uses a high dimensional approach to construct a comprehensive metabolic landscape of immune cells participating in the anti-viral response against SARS-CoV-2. Also encompassed within the invention are novel immune cell subsets exhibiting metabolic dysfunction that could serve as predictive biomarkers for COVID-19 severity or as targets for therapeutic interventions in COVID-19 disease.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD) is the most common liver disease with a worldwide prevalence estimated at 30% of the general population. To better understand the influence of MASLD progression on cardiovascular disease, the aim of the study was to develop a new physiopathological mouse model able to develop progressive MASLD, along with atherosclerosis development, in a reasonable period of time. LDLr - / - mice were crossed with PPARα-deficient mice in order to obtain LDLr- / - mice expressing (LDLr - / - PPARα + / +) or not (LDLr - / - PPARα - / -) PPARα. Female mice were challenged with a high-fat diet during 12 and 18 weeks. Histological liver analysis showed that, compared to control diet, LDLr - / - PPARα + / + mice under high fat diet developed mostly steatosis at 12 weeks, and then exhibited all characteristics of human MASLD, namely the steatosis, inflammation and ballooning-triad, with presence of fibrosis at 18 weeks. This MASLD progression over time in LDLr - / - PPARα + / + was aggravated in LDLr - / - PPARα + / + mice. The present invenion defines a new relevant mouse model of progressive MASLD, developing all the characteristics of human MASLD (steatosis, inflammation, ballooning, fibrosis), in a relatively short time period (12-18 weeks), along with simultaneous atherosclerosis development.

The invention discloses application of hesperidin in preparation of a medicine for preventing and / or treating porcine contagious pleuropneumonia, and belongs to the field of biological medicine. The concentration of the hesperidin is 6.25-25 [mu] g / mL, and cell experiments prove that the hesperidin can inhibit cell inflammatory response and reduce expression of inflammatory factors, and can effectively relieve the actinobacillus pleuropneumoniae induced endovascular dermatitis injury by inhibiting activation of CD14 / TLR4-NF [kappa] B P65. Animal experiments prove that the hesperidin can relieve pathological changes and injuries of various tissues and organs after actinobacillus pleuropneumoniae infection, improve weight loss caused by actinobacillus pleuropneumoniae infection, relieve inflammatory response and metabolic dysfunction caused by actinobacillus pleuropneumoniae, and improve the body weight loss caused by actinobacillus pleuropneumoniae. The composition plays a role in protecting organisms infected by actinobacillus pleuropneumoniae. The invention provides a new scientific basis for controlling porcine contagious pleuropneumonia by using natural medicines.

Provided herein are methods for detecting metabolic dysfunction or risk or presence of an age-associated disease in a subject. Also provided herein are methods for identifying a subject in need of treatment for metabolic dysfunction or risk or presence of an age-associated disease.

The invention discloses a synthetic microbial agent for treating uranium-contaminated soil and a preparation method of the synthetic microbial agent. The synthetic microbial agent is prepared from the following bacteria: P.adami, P.megatherium, bacillus subtilis, Artobacter volluticus, symbiotic fungi, Aspergillus niger, sulfate reducing bacteria and Shewanella. The symbiotic fungi are mucor lastein, mucor unimingguminum, mucor circinelloides, mucor dense, rhizopus arrhizus and phylum phthochytrium parasitic fungi. The prepared synthetic microbial agent and synthetic microbial embedded balls are applied to uranium-contaminated soil remediation, the key enzyme activity can be effectively improved, the soil metabolism function is enhanced, meanwhile, exchangeable uranium with high ecological risk is converted into stable and low-harm residual uranium, the mobility and bioavailability of uranium in soil are effectively weakened, and the uranium-contaminated soil remediation effect is improved. Therefore, immobilized remediation of uranium is realized, and a good soil uranium fixing effect is achieved.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention provides a composition for reducing uric acid and relieving gout and a preparation method thereof, and relates to the technical field of products for reducing uric acid and relieving gout. The composition comprises the following raw materials: 18-24 parts of phellinus igniarius, 9-13 parts of sunflower disc small molecule peptide extract, 3-7 parts of corn stigma, 4-6 parts of poria cocos, 2-5 parts of pawpaw, 3-6 parts of liquorice, 2-5 parts of astragalus extract and 3-6 parts of lettuce extract. The preparation method of the sunflower disc small-molecule peptide extract comprises the following steps: carrying out enzymolysis on sunflower disc powder twice, carrying out membrane filtration to obtain a sunflower disc small-molecule peptide solution, reacting the sunflower disc small-molecule peptide solution with chitosan oligosaccharide and transglutaminase, and carrying out freeze drying to obtain the sunflower disc small-molecule peptide extract. Through the proper raw material composition and proportion, the metabolic function can be effectively regulated to promote excretion of uric acid, so that the content of xanthine oxidase and adenosine deaminase in the liver is obviously reduced, the uric acid level is effectively reduced, the intestinal probiotic structure can be stabilized, the immunity is enhanced, the kidney is protected, and the good effects of reducing uric acid and relieving gout are achieved.

The invention relates to the technical field of medical assistance, in particular to a depression risk assessment method and system based on intestinal flora characteristics. The method comprises the following steps: acquiring an individual enteric microorganism sample, performing nucleic acid sequencing on the enteric microorganism sample, and determining abundance data of functional genes related to a neural activity metabolic pathway in enteric microorganisms; carrying out metabolite detection on the intestinal microorganism sample, and determining concentration data of metabolites related to the neural activity metabolic pathway in the intestinal microorganisms; based on the abundance data of the functional genes and the concentration data of the metabolites, data fusion processing is carried out, a neural activity metabolism function spectrum is constructed, and the neural activity metabolism function spectrum is a multi-dimensional feature vector; and inputting the neural activity metabolic function spectrum into a pre-trained risk assessment model, and outputting a depression risk score of the individual. The accuracy and repeatability of evaluation are remarkably improved, and the method has great potential for early screening, dynamic monitoring and personalized health management.

The invention provides a single strain metabolism characteristic chromatogram database of oral key microorganisms in a high-glucose microenvironment and a construction method and application thereof, and belongs to the technical field of oral microbiology. The method comprises the following steps: simulating an intraoral high-glucose microenvironment in vitro; the method comprises the following steps: carrying out standardized single-strain culture on oral key microorganisms, carrying out whole-spectrum metabolism detection (non-targeted liquid chromatography-mass spectrometry (LC-MS) and non-targeted gas chromatography-mass spectrometry (GC-MS) on culture supernatant, and identifying and analyzing metabolism to construct a single-strain metabolism characteristic spectrum database of the oral key microorganisms in a high-glucose microenvironment. The database can be used for source attribution and cross validation of in-vivo metabolome results, and assists in screening key metabolites and key pathways related to high glucose. According to the method, the reliability of metabolite source judgment is improved, the directional influence of high glucose on the flora metabolism function is revealed, the method is standardized, and resources are platformized.

The invention belongs to the technical field of bioengineering and microbiomics, and particularly relates to an acquisition method and application of a specific metabolic substrate of lactobacillus crispatus and application of a specific carbohydrate active enzyme CAZzyme gene and a polysaccharide utilization site (PUL). Genomes of lactobacillus crispatus and lactobacillus inertus are obtained from a public database, gene annotation is carried out on the genomes of the lactobacillus crispatus and the lactobacillus inertus, and a random forest model and a KEGG metabolic pathway diagram are combined to find specific CAZzyme genes, PUL and other genes with metabolic functions of the lactobacillus crispatus; a substrate which only lactobacillus crispatus can metabolize is searched based on the genome difference of the two bacteria, and the ability of the obtained substrate for promoting the growth of lactobacillus crispatus and inhibiting the growth of inert lactobacillus is evaluated through experiments. Growth and reproduction of the lactobacillus crispatus are promoted through the substrates, so that the lactobacillus crispatus accounts for a higher proportion in vagina microecology, the vagina is protected, and reproduction of other unfavorable bacteria is reduced. The assisted reproduction success rate is improved.

This invention provides a method for monitoring and evaluating the risk of pathogenic bacteria transmission in poultry farm feces, belonging to the field of livestock and poultry biosecurity control technology. The method includes evaluating the risk of Salmonella transmission during the poultry physiological cycle, assessing the risk of antibiotic resistance associated with drug administration behavior, and monitoring the function during composting based on microbial community structure and metabolic function. This invention can accurately locate the highest-risk nodes of pathogen contamination and antibiotic resistance evolution during the breeding cycle, solving the problem of inaccurate identification of risk sources in existing technologies and avoiding poultry product contamination due to missed risk assessments. It overcomes the single-dimensional limitation of existing technologies that only detect the quantity of pathogens, comprehensively evaluating pathogen risk from phenotypic, molecular, and functional levels. The assessment results are more in line with the actual biosecurity needs of poultry farming, ultimately reducing the safety risks of poultry product contamination and the spread of antibiotic resistance.